These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 37178320)

  • 1. Biologic TNF-α Inhibitors for Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and TEN-SJS Overlap: A Study-Level and Patient-Level Meta-Analysis.
    Cao J; Zhang X; Xing X; Fan J
    Dermatol Ther (Heidelb); 2023 Jun; 13(6):1305-1327. PubMed ID: 37178320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome.
    Jacobsen A; Olabi B; Langley A; Beecker J; Mutter E; Shelley A; Worley B; Ramsay T; Saavedra A; Parker R; Stewart F; Pardo Pardo J
    Cochrane Database Syst Rev; 2022 Mar; 3(3):CD013130. PubMed ID: 35274741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Combination Therapy With Etanercept and Systemic Corticosteroids for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Observational Study.
    Zhang J; Lu CW; Chen CB; Wang CW; Chen WT; Cheng B; Ji C; Chung WH
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1295-1304.e6. PubMed ID: 35131514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review.
    Zhang S; Tang S; Li S; Pan Y; Ding Y
    J Dermatolog Treat; 2020 Feb; 31(1):66-73. PubMed ID: 30702955
    [No Abstract]   [Full Text] [Related]  

  • 5. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions.
    Wang CW; Yang LY; Chen CB; Ho HC; Hung SI; Yang CH; Chang CJ; Su SC; Hui RC; Chin SW; Huang LF; Lin YY; Chang WY; Fan WL; Yang CY; Ho JC; Chang YC; Lu CW; Chung WH;
    J Clin Invest; 2018 Mar; 128(3):985-996. PubMed ID: 29400697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positive experience with TNF-α inhibitor in toxic epidermal necrolysis resistant to high-dose systemic corticosteroids.
    Nikitina EA; Fomina DS; Markina UA; Andreev SS; Streltsov YV; Kruglova TS; Lebedkina MS; Karaulov AV; Lysenko MA
    Front Med (Lausanne); 2023; 10():1210026. PubMed ID: 37554504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF-α induced extracellular release of keratinocyte high-mobility group box 1 in Stevens-Johnson syndrome/toxic epidermal necrolysis: Biomarker and putative mechanism of pathogenesis.
    Nwikue G; Olsson-Brown A; Aboheimed N; Yip V; Jolly C; Luchian A; Ressel L; Sharma A; Bergfeld W; Ahmed S; Dickinson A; Pirmohamed M; Carr DF
    J Dermatol; 2023 Sep; 50(9):1129-1139. PubMed ID: 37269158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of etanercept for treatment of toxic epidermal necrolysis when toxic shock syndrome is in the differential.
    So N; Leavitt E; Aleshin M; Worswick S
    Dermatol Ther; 2018 Sep; 31(5):e12684. PubMed ID: 30175438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Review of Efficacy and Safety of Monotherapy and Combination Therapy With Biologic for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
    Sachdeva M; Maliyar K; Ponzo MG
    J Cutan Med Surg; 2021; 25(6):598-615. PubMed ID: 33631950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures.
    Schneider JA; Cohen PR
    Adv Ther; 2017 Jun; 34(6):1235-1244. PubMed ID: 28439852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etanercept treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Tian CC; Ai XC; Ma JC; Hu FQ; Liu XT; Luo YJ; Tan GZ; Zhang JM; Li XQ; Guo Q; Zeng FQ; Shi ZR; Wang L
    Ann Allergy Asthma Immunol; 2022 Sep; 129(3):360-365.e1. PubMed ID: 35598882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging Insights into Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Immune Checkpoint Inhibitor and Tumor-Targeted Therapy.
    Lin M; Gong T; Ruan S; Lv X; Chen R; Su X; Cheng B; Ji C
    J Inflamm Res; 2024; 17():2337-2351. PubMed ID: 38645875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxic epidermal necrolysis and Stevens-Johnson syndrome/toxic epidermal necrolysis overlap in pediatric patients with a focus on newer antiepileptic drugs: A 25-year retrospective study at a single tertiary care center.
    Gleghorn KL; Voigt C; Kelly B
    Pediatr Dermatol; 2021 Jul; 38(4):812-818. PubMed ID: 34060145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Immunomodulating Therapies for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-analysis.
    Zimmermann S; Sekula P; Venhoff M; Motschall E; Knaus J; Schumacher M; Mockenhaupt M
    JAMA Dermatol; 2017 Jun; 153(6):514-522. PubMed ID: 28329382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States and factors predictive of outcome.
    Wasuwanich P; So JM; Chakrala TS; Chen J; Motaparthi K
    JAAD Int; 2023 Dec; 13():17-25. PubMed ID: 37575514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Causative Drugs and Clinical Outcome in Stevens Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and SJS-TEN Overlap in Children.
    Sethuraman G; Sharma VK; Pahwa P; Khetan P
    Indian J Dermatol; 2012 May; 57(3):199-200. PubMed ID: 22707771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic kidney disease is potentially an independent prognostic factor for death in Stevens-Johnson syndrome and toxic epidermal necrolysis patients.
    Rattanakaemakorn P; Palakornkitti P; Pinyowiwat P; Jedee P; Thadanipon K
    Front Med (Lausanne); 2022; 9():939210. PubMed ID: 36091688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
    Yang Y; Xu J; Li F; Zhu X
    Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of multiple medical interventions on mortality, length of hospital stay and reepithelialization time in Toxic Epidermal Necrolysis, Steven-Johnsons Syndrome, and TEN/SJS Overlap - Metanalysis and metaregression of observational studies.
    Krajewski A; Maciejewska-Markiewicz D; Jakubczyk K; Markowska M; Strużyna J; Mądry R; Mazurek M; Skonieczna-Żydecka K
    Burns; 2022 Mar; 48(2):263-280. PubMed ID: 34903405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Patients Treated With a Medicine-Led Multidisciplinary Approach.
    Lewcun JA; Vagonis A; Kontzias C; Newsom M; Drake M; Feldman MJ
    J Burn Care Res; 2024 Jan; 45(1):165-168. PubMed ID: 37698266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.